Accepted for Publication: January 29, 2015.
Published Online: April 22, 2015. doi:10.1001/jamadermatol.2015.0214.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: Boespflug, Guerra, Thomas.
Drafting of the manuscript: Boespflug, Guerra, Thomas.
Critical revision of the manuscript for important intellectual content: Guerra, Dalle, Thomas.
Statistical analysis: Guerra.
Obtained funding: Thomas.
Administrative, technical, or material support: Thomas.
Study supervision: Dalle, Thomas.
Conflict of Interest Disclosures: Dr Dalle received basic science research grants from Roche. Dr Thomas has been, is, and will be principal investigator for the BRIM-3, coBRIM, BRIM-8, and COMBI-AD clinical trials, including trials of vemurafenib in either 1 or both treatment arms, but does not receive any personal honorarium. He is also the author or coauthor of several dermatology and dermoscopy textbooks for which he receives royalties. No other disclosures are reported.
Funding/Support: This study was supported in part by a grant from the Claude Bernard–Lyon 1 University. Dr Dalle received academic grants from Claude Bernard–Lyon 1 University. Dr Thomas receives grants for academic work and research activity from Claude Bernard–Lyon 1 University, Direction de la Recherche Clinique des Hospices Civils de Lyon, and la Ligue Contre le Cancer du Rhône.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.